Wang Q, Xie J, Liang J, Dong G, Ding L, Luo P
Molecules. 2019; 24(14).
PMID: 31319475
PMC: 6680384.
DOI: 10.3390/molecules24142593.
Hunter L, Wood D, Dargan P
Open Access Emerg Med. 2016; 3:39-48.
PMID: 27147851
PMC: 4753966.
DOI: 10.2147/OAEM.S22795.
Bowalgaha K, Elliot D, Mackenzie P, Knights K, Swedmark S, Miners J
Br J Clin Pharmacol. 2005; 60(4):423-33.
PMID: 16187975
PMC: 1884820.
DOI: 10.1111/j.1365-2125.2005.02446.x.
Faassen F, Vromans H
Clin Pharmacokinet. 2004; 43(15):1117-26.
PMID: 15568890
DOI: 10.2165/00003088-200443150-00004.
Borga O, Borga B
J Pharmacokinet Biopharm. 1997; 25(1):63-77.
PMID: 9353694
DOI: 10.1023/a:1025719827072.
Clinical pharmacokinetics of naproxen.
Davies N, Anderson K
Clin Pharmacokinet. 1997; 32(4):268-93.
PMID: 9113437
DOI: 10.2165/00003088-199732040-00002.
The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine.
Vree T, Vree M, Guelen P
Br J Clin Pharmacol. 1993; 35(5):467-72.
PMID: 8512758
PMC: 1381683.
DOI: 10.1111/j.1365-2125.1993.tb04171.x.
Jaundice associated with naproxen.
Victorino R, Silveira J, Baptista A, de Moura M
Postgrad Med J. 1980; 56(655):368-70.
PMID: 7443602
PMC: 2425629.
DOI: 10.1136/pgmj.56.655.368.
Pharmacokinetics of naproxen in subjects with normal and impaired renal function.
Anttila M, Haataja M, Kasanen A
Eur J Clin Pharmacol. 1980; 18(3):263-8.
PMID: 7439246
DOI: 10.1007/BF00563009.
Bioavailability of naproxen sodium and its relationship to clinical analgesic effects.
SEVELIUS H, Runkel R, Segre E, Bloomfield S
Br J Clin Pharmacol. 1980; 10(3):259-63.
PMID: 7437243
PMC: 1430062.
DOI: 10.1111/j.1365-2125.1980.tb01753.x.
Michaelis-Menten absorption kinetics in drugs: - examples and implications.
WOOD J, Thakker K
Eur J Clin Pharmacol. 1982; 23(2):183-8.
PMID: 7140809
DOI: 10.1007/BF00545976.
Pharmacokinetics of drug overdose.
Rosenberg J, Benowitz N, Pond S
Clin Pharmacokinet. 1981; 6(3):161-92.
PMID: 7016383
DOI: 10.2165/00003088-198106030-00001.
Naproxen disposition in patients with alcoholic cirrhosis.
Williams R, Upton R, Cello J, Jones R, Blitstein M, Kelly J
Eur J Clin Pharmacol. 1984; 27(3):291-6.
PMID: 6510456
DOI: 10.1007/BF00542162.
Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.
Verbeeck R, Blackburn J, Loewen G
Clin Pharmacokinet. 1983; 8(4):297-331.
PMID: 6352138
DOI: 10.2165/00003088-198308040-00003.
Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation.
van den Ouweland F, Franssen M, van de Putte L, Tan Y, van Ginneken C, Gribnau F
Br J Clin Pharmacol. 1987; 23(2):189-93.
PMID: 3828195
PMC: 1386067.
DOI: 10.1111/j.1365-2125.1987.tb03028.x.
Hypoalbuminaemia and naproxen pharmacokinetics in a patient with rheumatoid arthritis.
van den Ouweland F, Gribnau F, Tan Y, van Ginneken C, van de Putte L
Clin Pharmacokinet. 1986; 11(6):511-5.
PMID: 3802691
DOI: 10.2165/00003088-198611060-00007.
Acute poisoning due to non-steroidal anti-inflammatory drugs. Clinical features and management.
Vale J, Meredith T
Med Toxicol. 1986; 1(1):12-31.
PMID: 3537613
DOI: 10.1007/BF03259825.
Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.
Lin J, Cocchetto D, DUGGAN D
Clin Pharmacokinet. 1987; 12(6):402-32.
PMID: 3301150
DOI: 10.2165/00003088-198712060-00002.
Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.
Verbeeck R
Clin Pharmacokinet. 1990; 19(1):44-66.
PMID: 2199127
DOI: 10.2165/00003088-199019010-00004.
Toxic effects of nonsteroidal anti-inflammatory drugs in overdose. An overview of recent evidence on clinical effects and dose-response relationships.
Smolinske S, HALL A, Vandenberg S, Spoerke D, McBride P
Drug Saf. 1990; 5(4):252-74.
PMID: 2198051
DOI: 10.2165/00002018-199005040-00003.